Potential MS drug RPC1063 meets primary objective ....

[MSUK]

Potential MS drug RPC1063 meets primary objective in TQT study

Receptos, Inc. said its oral, once daily, selective and potent S1P1R modulator RPC1063 completed a thorough QT/QTc or TQT study of herart's electrical conduction system and met its primary objective. The company also obtained special protocol assessments or SPA from FDA for Phase 3 Trials in Relapsing Multiple Sclerosis.

RPC1063 is currently in development for autoimmune indications and being studied in randomized Phase 2 trials for the treatment of relapsing multiple sclerosis and ulcerative colitis.... Read More - http://www.ms-uk.org/index.cfm/RPC1063

[CureOrBust]

So it Gilenya by a different company? But, who knows, it may be slightly better than Gilenya in human trials.
http://www.neurology.org/cgi/content/me ... ts/P05.157

a profile shared with the parent molecule. In preclinical species, RP101075 and RP101442 produce robust, dose dependent lymphopenia. RP101075 (0.1 and 0.3mpk) and RP0101442 (0.4 and 0.8mpk) had therapeutic benefit in MOG35-55 peptide induced mouse EAE, achieving efficacy equivalent to RPC1063 and FTY720 (Gilenya™).

[HarryZ]

So it Gilenya by a different company? But, who knows, it may be slightly better than Gilenya in human trials.

It appears that different drug companies are jumping on to the MS oral medication bandwagon. Looks like there's a lot of money to be made in this area!

Harry